

**NEW**  
OEM Antibodies  
Polyclonal Rabbit  
Anti-Human



SAA  
NGAL  
srCRP

Following our path on continuous innovation, we have added new OEM antibodies to our portfolio.

To know more, please contact us at  
[reagentpartnership@agilent.com](mailto:reagentpartnership@agilent.com)

---

## SAA

### Serum Amyloid A

SAA proteins are expressed in different isoforms. SAA1 and SAA2 are both acute phase proteins released from the liver. In response to inflammation and tissue damage, circulating SAA concentrations increase dramatically (1, 2). This polyclonal SAA antibody was raised against a recombinant version of SAA1.

## NGAL

### Neutrophil gelatinase-associated lipocalin

NGAL is a protein belonging to the lipocalin family, mostly expressed in neutrophils. NGAL levels in serum and urine are low under normal conditions, but a steep rise in NGAL level is seen in response to kidney injuries (3). The AKI status is useful 1) in monitoring cardiac surgery and intensive care patients, 2) as predictive evaluation after kidney transplant; and 3) in assessing nephrotoxicity when administering intravenous contrast agents (4, 5, 6).

## srCRP

### C-Reactive Protein, Slow-Reacting Antibody

CRP is produced in the liver and its level rises in response to inflammation. CRP assays are used for diagnosis of conventional inflammation (7) and low-grade inflammation for risk estimation of cardiovascular events (8, 9). The C-Reactive Protein, Slow-Reacting Antibody is to be used in a latex enhanced wide-range CRP assay. A wide-range CRP assay enables measurement of high and low CRP values in a single determination (10).

---

## References

1. Rosenthal CJ, Franklin EC. Variation with age and disease of an amyloid A protein-related serum component. *J Clin Invest.* 1975; 55(4):746-753.
2. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. *N Engl J Med.* 1999 Feb 11; 340(6):448-54.
3. Ronco C. NGAL: diagnosing AKI as soon as possible. *Crit Care.* 2007; 11(6):173.
4. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, et al.: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. *Lancet* 2005; 365:1231-1238.
5. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, Lee HT: Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. *Anesthesiology* 2006; 105:485-491.
6. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. *Biomark Med.* 2010 Apr; 4(2):265-80.
7. Colley CM, Fleck A, Goode AW, Muller BR, Myers MA. Early time course of the acute phase protein response in man. *J Clin Pathol.* 1983 Feb; 36(2):203-7.
8. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. *Circulation.* 1998 Aug 25; 98(8):731-3.
9. Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. *Circulation.* 1999 Jan 19; 99(2):237-42.
10. Vukovich TC, Mustafa S, Rumpold H, Wagner O. Evaluation of a turbidimetric Denka Seiken C-reactive protein assay for cardiovascular risk estimation and conventional inflammation diagnosis. *Clin Chem.* 2003 Mar; 49(3):511-2.



**Agilent Reagent Solutions**

[www.agilent.com](http://www.agilent.com)  
Represented in more  
than 50 countries

Agilent Technologies Denmark ApS  
Produktionsvej 42  
DK-2600 Glostrup  
Denmark

Tel. +45 44 85 95 00  
[reagentpartnership@agilent.com](mailto:reagentpartnership@agilent.com)